Of the patients who received a DPP-4 inhibitor, 41.90% had hypertension, 17.32% had hyperlipidemia, 8.38% had CAD, 4.90% had arrhythmia, 3.08% had heart failure, 1.75% had CKD, and 0.49% had obesity. The gene discussed is DPP4; the disease is hyperlipidemia.